Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Preiningerova, JL; Baumhackl, U; Csepany, T; Czaplinski, A; Deisenhammer, F; Derfuss, T; Fabjan, TH; Fazekas, F; Fuchs, S; Havrdova, E; Ledinek, AH; Illes, Z; Jazbec, SS; Klimova, E; Komoly, S; Kurca, E; Linnebank, M; Lisy, L; Mares, J; Prochazkova, L; Csilla, R; Szilasiova, J; Stourac, P; Talab, R; Turcani, P; Vachova, M; Vecsei, L; Vodusek, D; Zapletalova, O; Berger, T.
Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).
CNS Neurosci Ther. 2013; 19(5):302-306 Doi: 10.1111/cns.12101 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Fazekas Franz
Fuchs Siegrid

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Prolonged-release fampridine (fampridine PR) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management. © 2013 Blackwell Publishing Ltd.
Find related publications in this database (using NLM MeSH Indexing)
4-Aminopyridine - adverse effects 4-Aminopyridine - pharmacology 4-Aminopyridine - therapeutic use
Chemistry, Pharmaceutical -
Clinical Trials, Phase III as Topic -
Dose-Response Relationship, Drug -
Humans -
Multiple Sclerosis - drug therapy
Potassium Channel Blockers - therapeutic use
Practice Guidelines as Topic -

Find related publications in this database (Keywords)
Multiple sclerosis
© Med Uni Graz Impressum